Menopause Testosteronology®: Estrogen, Progesterone, And Testosterone Therapy For Women

014 Lesson 1 

41 MINUTE COURSE TRAINING VIDEO

With Colette Nelson, FNP-C, RD, CDCES, MSCP, Certified Testosteronologist®

014 Lesson 2 

49 MINUTE COURSE TRAINING VIDEO

With Colette Nelson, FNP-C, RD, CDCES, MSCP, Certified Testosteronologist®

014 Lesson 3 

33 MINUTE COURSE TRAINING VIDEO

With Colette Nelson, FNP-C, RD, CDCES, MSCP, Certified Testosteronologist®

Video Lesson Takeaways

◉ Menopause is an endocrine transition that can affect vasomotor function, sleep, bone, genitourinary tissue, sexual health, mood, and metabolic health.

◉ The Women’s Health Initiative studied specific oral hormone regimens in a population substantially older than many women who begin treatment near menopause.

◉ Estrogen treatment should reflect symptoms, age, time since menopause, uterine status, medical history, route-related risk, and patient goals.

◉ Oral estrogen undergoes first-pass hepatic metabolism, while transdermal estradiol avoids that pathway.

◉ Serum estradiol can be useful in selected cases, but routine menopause treatment should not revolve around a universal laboratory target.

◉ Micronized progesterone and synthetic progestins have clinically important pharmacologic differences.

◉ Women with an intact uterus generally require adequate progestogen protection when receiving systemic estrogen.

◉ Previous endometrial ablation does not reliably eliminate all estrogen-responsive endometrial tissue.

◉ Oral micronized progesterone can influence sleep and sedation, with substantial variation in individual tolerability.

◉ Persistent or unexpected bleeding requires clinical evaluation rather than repeated empirical hormone adjustments.

◉ No systemic testosterone product is FDA-approved specifically for women in the United States.

◉ Hypoactive sexual desire disorder is the only evidence-based indication for systemic testosterone therapy in postmenopausal women.

◉ Female testosterone treatment requires substantially lower exposure than male testosterone treatment and should remain within the physiologic female range.

◉ Transdermal testosterone has the strongest evidence base, while injections, pellets, troches, and compounded preparations introduce additional dosing considerations.

◉ Testosterone laboratory monitoring is primarily a safety tool and does not diagnose HSDD or replace clinical assessment.

◉ Acne, unwanted hair, scalp hair thinning, voice changes, and clitoral enlargement should prompt reassessment of androgen exposure.

◉ Physiologic female testosterone treatment is not equivalent to anabolic steroid use for physique or performance.

◉ Direct questioning about anabolic steroids, SARMs, growth hormone, peptides, and other enhancement compounds can materially change endocrine interpretation.

◉ Genitourinary syndrome of menopause may affect vaginal tissue, urinary symptoms, sexual comfort, and sexual desire.

◉ Women’s hormone care is strongest when each intervention has a defined clinical purpose and the whole patient remains part of follow-up.
 

 COURSE 014 TEXT 

①  Menopause As A Clinical Hormone Transition

Menopause is more than the end of menstruation. Ovarian estrogen and progesterone production becomes increasingly variable during perimenopause and ultimately declines, while androgen physiology also changes with age, ovarian surgery, illness, and medication exposure. These changes can affect thermoregulation, sleep, bone, genitourinary tissue, sexual function, mood, and cardiometabolic health.[1]

The transition can be clinically difficult to capture because symptoms often begin while menstrual cycles continue. A single hormone value may poorly represent weeks of fluctuating ovarian activity. Menstrual history, cycle changes, age, hysterectomy or oophorectomy, medication use, and symptom timing frequently provide more useful context than broad laboratory panels.

Common complaints still require a differential diagnosis. Fatigue, poor sleep, cognitive concerns, low libido, palpitations, and body-composition changes overlap with thyroid disease, anemia, diabetes, sleep apnea, depression, medication effects, and other conditions. The patient with severe night sweats, the woman with premature ovarian insufficiency, and the woman whose primary problem is painful intercourse are all experiencing hormone-related care needs, but they do not require the same treatment plan.[1]

②  The Women’s Health Initiative And Modern Estrogen Care

The Women’s Health Initiative changed menopause medicine in 2002 when the combined hormone trial reported that the risks of conjugated equine estrogen plus medroxyprogesterone acetate exceeded the benefits for chronic disease prevention in the population studied. Breast cancer, cardiovascular disease, stroke, and thromboembolic outcomes quickly became the public narrative around hormone therapy, and prescribing declined sharply.[3]

The trial remains essential evidence, but its population and purpose matter. Participants in the combined trial averaged approximately sixty-three years of age, many were years beyond the menopausal transition, and the regimen was oral conjugated equine estrogen with medroxyprogesterone acetate. The study was not designed primarily to determine the best treatment for a recently menopausal woman seeking relief from hot flashes or night sweats.[3]

Later analyses demonstrated that treatment outcomes were not uniform across the estrogen-alone and estrogen-plus-progestin arms. Age, time since menopause, baseline health, treatment type, and whether a progestogen was used all influenced interpretation.[4,5] The long-term breast cancer findings also differed between the two randomized treatment groups.[5]

Regulatory language has continued to evolve. In February 2026, the FDA approved revised labeling for six menopausal hormone therapy products that removed specified boxed-warning statements concerning cardiovascular disease, breast cancer, and probable dementia. Endometrial cancer warnings remain relevant to systemic estrogen-alone treatment in women with a uterus.[2]

The practical lesson is that “hormone therapy” is too broad a phrase for meaningful risk assessment. Clinical decisions should reflect the woman being treated and the actual formulation, route, dose, and indication under consideration.

③  Patient Selection, Timing, And Risk Assessment

Systemic estrogen remains the most effective treatment for bothersome vasomotor symptoms and prevents bone loss while treatment continues. For many healthy symptomatic women younger than sixty years or within approximately ten years of menopause onset, the benefit-risk relationship is generally favorable when contraindications are absent.[1]

Patient selection begins with history. Timing of the final menstrual period, uterine and ovarian status, previous hormone treatment, bleeding, breast history, thromboembolic disease, cardiovascular disease, liver disease, migraine, smoking, medications, blood pressure, diabetes, dyslipidemia, and obesity can alter the decision or preferred route.

Initiating treatment much later after menopause deserves greater caution because absolute cardiovascular and thrombotic risk rises with age. That is different from declaring that hormone therapy must stop at a fixed birthday. Ongoing treatment can remain appropriate for selected women when indication, benefit, and risk are reassessed periodically.[1]

Unexplained postmenopausal bleeding requires evaluation. Serious thromboembolic, cardiovascular, hepatic, or estrogen-sensitive disease may call for avoidance of systemic therapy or coordination with another specialist. The chart should make clear what problem is being treated, what risks were considered, and why the selected approach fits that patient.

④  Estrogen Formulations, Routes, And Treatment Individualization

Route changes estrogen pharmacology. Oral estrogen undergoes first-pass hepatic metabolism and can affect coagulation factors, triglycerides, inflammatory pathways, and hormone-binding proteins. Transdermal estradiol bypasses first-pass hepatic metabolism, and observational evidence has associated transdermal treatment with lower venous thromboembolic risk than oral estrogen.[6]

Patient adherence and medication administration are important as well. Patches provide standardized doses but can loosen, irritate the skin, or be replaced inconsistently. Gels and sprays require reliable application and transfer precautions. Oral preparations may be easier for some women to use consistently. A theoretically ideal formulation has limited value if the patient cannot use it correctly.

Dose escalation should follow the clinical response rather than happen automatically. Poor patch adhesion, missed doses, or inconsistent topical application can resemble treatment failure. Breast tenderness, headache, fluid changes, or new bleeding may point in the other direction and warrant reassessment.

Routine menopausal therapy does not require titration toward one universal estradiol value.[1] Laboratory testing becomes more useful when absorption is uncertain, the response is unexpected, or the result would change management. Changing one major variable at a time also makes it easier to identify what produced improvement or intolerance.

⑤  Progesterone, Progestins, And Endometrial Protection

Progesterone refers to the endogenous hormone and preparations such as micronized progesterone that are chemically identical to it. Progestogen is the broader category that includes progesterone and synthetic progestins such as medroxyprogesterone acetate and levonorgestrel. Their endometrial effects overlap, but their pharmacology is not identical.

Women with an intact uterus receiving systemic estrogen generally require adequate progestogen protection. Unopposed estrogen stimulates endometrial proliferation and increases the risk of hyperplasia and endometrial cancer over time.[1,8]

Adequate protection depends on dose, schedule, adherence, and the estrogen regimen being used. A prescription on the medication list does not prove that the woman is taking it correctly. Missed doses, misunderstood cyclic schedules, or intolerance may leave the endometrium insufficiently protected. Available evidence also does not support relying on transdermal micronized progesterone for endometrial protection.[8]

Women who have undergone total hysterectomy generally do not require a progestogen for uterine protection. If micronized progesterone is used for sleep or another individualized reason, the rationale should be considered separately from endometrial protection.

⑥  Micronized Progesterone, Sleep, Bleeding, And Tolerability

Oral micronized progesterone is metabolized in part to neuroactive compounds, including allopregnanolone, which modulate GABA-A receptors. Clinical evidence suggests improvement in selected sleep outcomes for some postmenopausal women.[9] This helps explain why bedtime administration is common.

The response is highly individual. One woman may sleep substantially better, while another wakes sedated, dizzy, or cognitively slowed. Mood changes, bloating, and gastrointestinal symptoms can also limit adherence. Sleep complaints still deserve evaluation for sleep apnea, insomnia, alcohol effects, psychiatric conditions, and other causes rather than being attributed automatically to hormone status.

Progesterone can be given continuously or cyclically depending on menopausal stage, treatment strategy, and bleeding goals. Continuous regimens are often used after menopause, while cyclic therapy may create a predictable withdrawal bleed. Either approach requires a schedule the patient understands and follows. 

Menopausal hormone therapy should not be considered contraception. Ovulation can still occur during perimenopause, and women who remain at risk of pregnancy require a separate contraceptive strategy. Contraceptive needs, bleeding patterns, and the need for endometrial protection should therefore be considered separately when selecting a hormone regimen.

Bleeding after treatment begins should be characterized by timing, frequency, duration, and volume. Early spotting can occur, but persistent, heavy, recurrent, or newly developed bleeding after established amenorrhea requires evaluation. Medication adherence and recent hormone changes belong in that assessment, along with structural uterine and cervical causes.

Endometrial ablation deserves particular attention because residual functioning endometrial tissue can remain. A woman who retains her uterus after ablation should not be assumed to have the same endometrial risk as a woman who has undergone hysterectomy. If systemic estrogen is used, an adequate protective strategy generally remains necessary.

When oral micronized progesterone is not tolerated, other progestogens or an appropriate levonorgestrel-releasing intrauterine system may provide alternative endometrial protection. Individualization can change the drug or delivery method without removing the need for endometrial protection.

⑦ Testosterone Physiology And Clinical Indications In Women

Testosterone is part of normal female physiology. Women produce testosterone through ovarian and adrenal pathways, with additional contribution from peripheral conversion. Androgen signaling participates in sexual function and other physiologic processes throughout life.

Systemic testosterone treatment may be considered for postmenopausal women with hypoactive sexual desire disorder after a biopsychosocial assessment. The Global Consensus Position Statement identifies HSDD as the only evidence-based indication for testosterone therapy in women, and ISSWSH provides detailed prescribing and monitoring guidance for this population.[10,11]

HSDD is not diagnosed by a serum testosterone value. Persistent reduced desire must cause personal distress and should not be better explained by another medical problem, medication, psychological condition, relationship factor, or painful sexual activity. Genitourinary symptoms, depression, sleep disruption, antidepressant therapy, chronic illness, and partner factors can all contribute.

Clinical trials demonstrate modest improvement in sexual desire, arousal, orgasmic function, and satisfaction in appropriately selected women. Current evidence does not support prescribing testosterone to prevent cardiovascular disease, cognitive decline, osteoporosis, sarcopenia, or generalized aging-related symptoms.[10]

⑧  Female Testosterone Formulations And Conservative Dosing

No systemic testosterone product is FDA-approved specifically for women in the United States. Commercial products approved for male hypogonadism may be prescribed off-label when they can be reduced reliably to an appropriate female dose.[11]

The dosing difference is substantial. Products intended for men contain far more testosterone than women usually require, so small measurement errors can produce large proportional changes in exposure. Conservative initial dosing, proper patient education and gradual adjustment are fundamental safeguards.

Transdermal testosterone has the strongest evidence base. When an appropriate female product is unavailable, guidance supports cautious use of a male transdermal formulation at approximately one-tenth of the male dose while maintaining testosterone within the physiologic premenopausal female range.[11]

Compounded preparations can offer lower concentrations, but efficacy and safety data and quality-control consistency are limited. When an appropriate commercial formulation can be accurately dose-adjusted, it is generally preferred. Injectable preparations manufactured for men can also be difficult to measure accurately at female doses. Troches have compounded-product and absorption concerns. Pellets cannot be readily adjusted after implantation and may expose the patient to prolonged supraphysiologic levels.[10,11]

The treatment goal is a meaningful response to the established indication with physiologic female exposure. Male reference ranges, bodybuilding effects, and arbitrary “optimal” testosterone targets are not appropriate objectives.

⑨ Monitoring Testosterone And Preventing Virilization

Baseline total testosterone provides a reference point and helps identify unexpectedly high exposure before treatment. It does not diagnose HSDD. Sex hormone-binding globulin can add context in selected patients.[11]

Follow-up testing should occur after treatment begins and after significant dose changes. Sampling needs to make sense for the formulation because timing can materially alter interpretation.[10,11]

Clinical response must be assessed alongside laboratory results. The clinician should determine whether the original sexual concern and associated distress have meaningfully improved. If an adequate therapeutic trial produces no useful benefit, continued dose escalation is difficult to justify.
Acne and increased facial or body hair may be early signs of excessive androgen exposure. Scalp hair thinning can also occur. Voice deepening and clitoral enlargement are more concerning because they may not fully reverse.

When adverse effects appear, review the product, concentration, dose, measuring technique, administration schedule, pharmacy source, and laboratory timing. Correcting excessive exposure is generally more appropriate than adding another medication to counteract an avoidable androgen effect.

⑩  Physiologic Testosterone Versus Anabolic Steroid Exposure

Women seeking hormone care may also be exposed to physique-oriented drug advice. Some arrive having been told to suppress estrogen, use oxandrolone, or pursue androgen levels intended for appearance or performance rather than health. 

Physiologic testosterone treatment is different from anabolic-androgenic steroid use. The indication, exposure, pharmacology, and risk tolerance are different. Oxandrolone, stanozolol, nandrolone, and other anabolic agents should not be reclassified as menopausal hormone replacement simply because they interact with androgen receptors.

Anabolic steroid use occurs among women, particularly within bodybuilding and strength-focused populations. A 2024 systematic review found substantially greater lifetime exposure among female bodybuilders than among women in the general population, although prevalence estimates varied across studies.[14]

The clinical history should therefore ask directly about anabolic steroids, SARMs, growth hormone, peptides, aromatase inhibitors, and other performance-enhancing drugs. Compound, dose, duration, goals, menstrual changes, adverse effects, and previous attempts to stop can all affect endocrine interpretation.

Supraphysiologic AAS exposure may produce virilization, adverse lipid changes, reproductive suppression, psychiatric effects, and other organ-system consequences. Some orally active anabolic steroids are also associated with clinically important liver injury.[15] The appropriate response is an accurate exposure history and risk assessment without confusing enhancement use with evidence-based female testosterone therapy.

⑪ Genitourinary Syndrome Of Menopause And Sexual Health

Genitourinary syndrome of menopause can affect the vagina, vulva, lower urinary tract, and sexual function. Women may report dryness, burning, irritation, reduced lubrication, painful intercourse, urinary urgency, dysuria, or recurrent urinary tract infections.[7,12]

These symptoms often persist or worsen over time even after hot flashes improve. Asking directly matters because many women do not volunteer them. A complaint described as “low libido” may partly reflect the fact that sexual activity has become painful.

Low-dose vaginal estrogen is an effective local treatment and is available as creams, tablets, inserts, and rings. Evidence supports improvement in vaginal dryness, dyspareunia, and several urinary symptoms.[12] Vaginal estrogen is also used in appropriate postmenopausal women as part of recurrent urinary tract infection prevention strategies.[13]

Local therapy and systemic therapy serve different purposes. Vaginal estrogen should not be expected to treat significant systemic vasomotor symptoms, while systemic estrogen does not guarantee complete relief of genitourinary symptoms. Some women require both approaches.

Prasterone, vaginal moisturizers, and lubricants provide additional options for selected patients. Persistent pain should prompt evaluation for infection, pelvic floor dysfunction, vulvodynia, lichen sclerosus, and other conditions rather than repeated hormone adjustment.

⑫  The Clinical Direction Of Women’s Care In Testosteronology®

Women’s hormone care becomes more precise when each problem is considered separately. Systemic estrogen may address vasomotor symptoms. Local estrogen may be needed for genitourinary tissue. A progestogen may be required for uterine safety. Micronized progesterone may also affect sleep. Testosterone may be appropriate for a carefully evaluated sexual desire disorder. The patient may need several of these interventions, one of them, or none.

Hormone treatment does not replace broader medical care. Blood pressure, glycemic status, lipid risk, weight trajectory, sleep, bone health, breast screening, uterine health, mood, sexual function, medications, and exercise remain relevant throughout treatment. ABCDS™ can support longitudinal monitoring, while women’s hormone care adds specific attention to gynecologic history, bleeding, genitourinary symptoms, and signs of androgen excess. 

A detailed medication reference summarizing FDA-approved products discussed in this course, including formulations, labeled indications, labeled dosing, and relevant clinical considerations, is provided as a downloadable course resource. 

 COURSE 014 SUMMARY 

Menopause can affect multiple physiologic and quality-of-life domains, and hormone treatment should reflect the symptoms and risks of the individual woman. The Women’s Health Initiative remains important evidence, but its findings must be understood within the population, formulations, and prevention strategy that were actually studied. Estrogen route, dose, timing, uterine status, and patient risk all affect clinical decision-making.

Women with an intact uterus receiving systemic estrogen generally require adequate progestogen protection. Micronized progesterone and synthetic progestins are not pharmacologically identical, and oral micronized progesterone may influence sleep in some patients. Bleeding, medication adherence, treatment tolerability, and previous endometrial ablation require deliberate assessment.

Testosterone is part of normal female physiology, but HSDD in appropriately evaluated postmenopausal women remains the only evidence-based indication for systemic testosterone therapy. Because no systemic testosterone product is FDA-approved specifically for women in the United States, prescribing requires careful dose selection, informed consent, physiologic female exposure, laboratory monitoring, and surveillance for androgenic adverse effects.

Female testosterone treatment should also be distinguished from anabolic-androgenic steroid use for physique or performance. Those exposures belong in the clinical history because they can alter endocrine physiology and risk. Genitourinary health, sexual pain, mood, sleep, medications, relationship factors, cardiovascular and metabolic health also remain part of the assessment.
Each hormone should have a defined purpose, each treatment should be reassessed, and clinical success should be measured by meaningful benefit achieved without losing sight of long-term health.
 

 COURSE 014 EVALUATION 

 COURSE 014 REFERENCES 

1.  The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
2.  U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. Published February 12, 2026.
3.  Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
4.  Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
5.  Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380.
6.  Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens. Circulation. 2007;115(7):840-845.
7.  The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
8.  Stute P, Wildt L, Neulen J. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316-328.
9.  Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis of randomized controlled trial data. J Clin Endocrinol Metab. 2021;106(4):e942-e951.
10.  Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Climacteric. 2019;22(5):429-434.
11.  Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849-867.
12.  Rahn DD, Carberry C, Sanses TVD, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-1156.
13.  Buck ES, Lukas VA, Rubin RS. Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause. Urology. 2021;151:31-36.
14.  Piatkowski T, Whiteside B, Robertson J, et al. What is the prevalence of anabolic-androgenic steroid use among women? A systematic review. Addiction. 2024;119(12):2088-2100.
15.  Petrovic A, Vukadin S, Sikora R, et al. Anabolic androgenic steroid-induced liver injury: an update. World J Gastroenterol. 2022;28(26):3071-3080.
    
     

Recommended Grand Rounds Case Reviews